Delta 9 Cannabis Inc
Humble Grow Co., together with its subsidiaries, operates as an integrated cannabis company. The company engages in the cultivation, processing, extraction, wholesale distribution, retail, and sale of medical and recreational cannabis products. Its products include dried cannabis flowers, pre-rolls, and dried sift cannabis, as well as oils, and extracted and derivative products. The company also … Read more
Delta 9 Cannabis Inc (DLTNF) - Net Assets
Latest net assets as of March 2024: $-9.96 Million USD
Based on the latest financial reports, Delta 9 Cannabis Inc (DLTNF) has net assets worth $-9.96 Million USD as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($70.23 Million) and total liabilities ($80.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-9.96 Million |
| % of Total Assets | -14.18% |
| Annual Growth Rate | N/A |
| 5-Year Change | -118.67% |
| 10-Year Change | N/A |
| Growth Volatility | 203.86 |
Delta 9 Cannabis Inc - Net Assets Trend (2003–2023)
This chart illustrates how Delta 9 Cannabis Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Delta 9 Cannabis Inc (2003–2023)
The table below shows the annual net assets of Delta 9 Cannabis Inc from 2003 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-6.43 Million | -198.29% |
| 2022-12-31 | $6.54 Million | -74.13% |
| 2021-12-31 | $25.28 Million | -27.45% |
| 2020-12-31 | $34.85 Million | +1.21% |
| 2019-12-31 | $34.43 Million | -2.48% |
| 2018-12-31 | $35.31 Million | +43.77% |
| 2017-12-31 | $24.56 Million | +16267.22% |
| 2016-12-31 | $-151.89K | +66.24% |
| 2015-12-31 | $-449.86K | +25.92% |
| 2014-12-31 | $-607.27K | -31.95% |
| 2013-12-31 | $-460.23K | +57.86% |
| 2012-12-31 | $-1.09 Million | -84.53% |
| 2011-12-31 | $-591.90K | -2031.59% |
| 2010-12-31 | $-27.77K | -104.40% |
| 2009-12-31 | $631.75K | +139.64% |
| 2008-12-31 | $263.62K | -92.50% |
| 2007-12-31 | $3.51 Million | -47.04% |
| 2006-12-31 | $6.64 Million | +677.91% |
| 2005-12-31 | $853.10K | +15.98% |
| 2004-12-31 | $735.58K | -4.62% |
| 2003-12-31 | $771.18K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Delta 9 Cannabis Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7178317700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $76.40 Million | % |
| Other Comprehensive Income | $-19.27 Million | % |
| Other Components | $7.68 Million | % |
| Total Equity | $-7.28 Million | 100.00% |
Delta 9 Cannabis Inc Competitors by Market Cap
The table below lists competitors of Delta 9 Cannabis Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BALOISE HLDG N - Dusseldorf Stock Exchang
DU:BLON
|
$2.12 Million |
|
Rewardle Holdings Ltd
AU:RXH
|
$2.12 Million |
|
APPLIED IND TECH
BE:AT4
|
$2.12 Million |
|
DSV - Dusseldorf Stock Exchang
DU:DS81
|
$2.12 Million |
|
Newcity (Bangkok) Public Company Limited
BK:NC
|
$2.12 Million |
|
Reliability Incorporated
PINK:RLBY
|
$2.12 Million |
|
Orgabio Holdings Bhd
KLSE:0252
|
$2.12 Million |
|
MAS Gold Corp
PINK:MSGCF
|
$2.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Delta 9 Cannabis Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 6,564,821 to -7,279,905, a change of -13,844,726 (-210.9%).
- Net loss of 17,515,339 reduced equity.
- New share issuances of 1,924,058 increased equity.
- Other factors increased equity by 1,746,555.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.52 Million | -240.6% |
| Share Issuances | $1.92 Million | +26.43% |
| Other Changes | $1.75 Million | +23.99% |
| Total Change | $- | -210.89% |
Book Value vs Market Value Analysis
This analysis compares Delta 9 Cannabis Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $5.35 | $0.01 | x |
| 2004-12-31 | $3.03 | $0.01 | x |
| 2005-12-31 | $1.70 | $0.01 | x |
| 2006-12-31 | $6.40 | $0.01 | x |
| 2007-12-31 | $3.28 | $0.01 | x |
| 2008-12-31 | $0.25 | $0.01 | x |
| 2009-12-31 | $0.59 | $0.01 | x |
| 2010-12-31 | $-0.03 | $0.01 | x |
| 2011-12-31 | $-6.08 | $0.01 | x |
| 2012-12-31 | $-1.02 | $0.01 | x |
| 2013-12-31 | $-0.43 | $0.01 | x |
| 2014-12-31 | $-0.57 | $0.01 | x |
| 2015-12-31 | $-0.42 | $0.01 | x |
| 2016-12-31 | $-0.03 | $0.01 | x |
| 2017-12-31 | $0.50 | $0.01 | x |
| 2018-12-31 | $0.44 | $0.01 | x |
| 2019-12-31 | $0.38 | $0.01 | x |
| 2020-12-31 | $0.39 | $0.01 | x |
| 2021-12-31 | $0.24 | $0.01 | x |
| 2022-12-31 | $0.05 | $0.01 | x |
| 2023-12-31 | $-0.04 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Delta 9 Cannabis Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24.65%
- • Asset Turnover: 0.96x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-103.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -22.09% | 0.00% | 0.00x | 1.09x | $-247.47K |
| 2004 | -45.60% | 0.00% | 0.00x | 1.03x | $-408.96K |
| 2005 | -249.80% | 0.00% | 0.00x | 1.26x | $-2.22 Million |
| 2006 | -44.95% | 0.00% | 0.00x | 1.01x | $-3.65 Million |
| 2007 | -88.82% | -273.10% | 0.31x | 1.06x | $-3.47 Million |
| 2008 | -1269.51% | -257.98% | 1.81x | 2.72x | $-3.37 Million |
| 2009 | 58.27% | 72.73% | 0.46x | 1.75x | $304.96K |
| 2010 | 0.00% | -232.19% | 0.45x | 0.00x | $-1.19 Million |
| 2011 | 0.00% | -62.23% | 0.60x | 0.00x | $-280.45K |
| 2012 | 0.00% | -51.31% | 2.75x | 0.00x | $-80.19K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $678.04K |
| 2014 | 0.00% | -24.11% | 39.98x | 0.00x | $-86.32K |
| 2015 | 0.00% | 32.24% | 39.10x | 0.00x | $205.66K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-190.10K |
| 2017 | -31.98% | -833.65% | 0.04x | 1.02x | $-10.33 Million |
| 2018 | -23.93% | -112.11% | 0.16x | 1.30x | $-12.03 Million |
| 2019 | 39.91% | 43.27% | 0.48x | 1.92x | $10.30 Million |
| 2020 | -15.67% | -10.54% | 0.68x | 2.18x | $-8.98 Million |
| 2021 | -45.17% | -17.89% | 0.83x | 3.03x | $-13.61 Million |
| 2022 | -428.23% | -44.46% | 0.71x | 13.64x | $-28.77 Million |
| 2023 | 0.00% | -24.65% | 0.96x | 0.00x | $-16.79 Million |
Industry Comparison
This section compares Delta 9 Cannabis Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Delta 9 Cannabis Inc (DLTNF) | $-9.96 Million | -22.09% | N/A | $2.12 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |